Fosun snatches GSK plant in China by Eric Palmer Tuesday, July 9, 2019 Even as GlaxoSmithKline has opened its most advanced manufacturing site in Asia, it is selling an older plant in China to Fosun Pharma.
Heplisav-B; Janssen and more—News of Note by Angus Liu Wednesday, February 27, 2019 Here is some other vaccine news of note for the week.
U.S. biotech focused on China to build manufacturing facility by Eric Palmer Monday, November 19, 2018 A U.S. biotech that bought nearly 30 generic drugs from Sandoz in January says it has plans to build its first manufacturing facility in China.
Dynavax, Emergent and more—News of Note by Angus Liu Wednesday, August 8, 2018 Here is some other vaccine news of note for the week.
Dynavax secures $175M for Heplisav-B marketing, I-O studies by Angus Liu Tuesday, February 20, 2018 The loan and the $192 million cash left at the end of 2017 will support a Heplisav-B sales team and the clinical trials of SD-101.
Google backs universal flu vaccine developer Vaccitech by Angus Liu Tuesday, January 16, 2018 The £20 million series A backed by GV will help Vaccitech develop an MVA-vectored universal flu vaccine currently in phase 2.
VBI’s hep B shot in pivotal trial against GSK's Engerix-B by Angus Liu Tuesday, December 19, 2017 VBI Vaccines is aiming for 2019 approval filings for its hepatitis B vaccine if a head-to-head trial against GSK's entrenched Engerix-B succeeds.
Merck, GSK face hep A vaccine shortage amid U.S. outbreaks by Angus Liu Tuesday, November 14, 2017 Merck and GSK are coping with hepatitis A vaccine shortages as the U.S. is experiencing deadly outbreaks.
Set on challenging GSK, Dynavax gears up for Heplisav launch by Eric Sagonowsky Monday, September 25, 2017 Dynavax is assuming the daunting task of challenging a Big Pharma with a small internal team.
VBI Vaccines, BiondVax and more—News of Note by Eric Sagonowsky Tuesday, September 5, 2017 Here's other vaccine news of note for this week.
